Metabolic profiling of CSF:Evidence that early intervention may impact on disease progression and outcome in schizophrenia by Holmes, Elaine et al.
                                                              
University of Dundee
Metabolic profiling of CSF
Holmes, Elaine; Tsang, Tsz M.; Huang, Jeffrey T.J.; Leweke, F. Markus; Koethe, Dagmar;
Gerth, Christoph W.; Nolden, Brit M.; Gross, Sonja; Schreiber, Daniela; Nicholson, Jeremy K.;
Bahn, Sabine
Published in:
PLoS Medicine
DOI:
10.1371/journal.pmed.0030327
Publication date:
2006
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Holmes, E., Tsang, T. M., Huang, J. T. J., Leweke, F. M., Koethe, D., Gerth, C. W., ... Bahn, S. (2006).
Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in
schizophrenia. PLoS Medicine, 3(8), 1420-1428. https://doi.org/10.1371/journal.pmed.0030327
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Metabolic Profiling of CSF: Evidence That
Early Intervention May Impact on Disease
Progression and Outcome in Schizophrenia
Elaine Holmes
1[
, Tsz M. Tsang
1[
, Jeffrey T.-J. Huang
2[
, F. Markus Leweke
3[
, Dagmar Koethe
3
, Christoph W. Gerth
3
,
Brit M. Nolden
3
, Sonja Gross
3
, Daniela Schreiber
3
, Jeremy K. Nicholson
1
, Sabine Bahn
2*
1 Biological Chemistry, Biomedical Sciences Division, Faculty of Medicine, Imperial College, London, United Kingdom, 2 Institute of Biotechnology, University of Cambridge,
Cambridge, United Kingdom, 3 Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
Funding: The study was funded
through grants from the Stanley
Medical Research Institute (USA) and
the Henry Smith Charity (UK). The
funders had no role in study design,
data collection and analysis, decision
to publish, or preparation of the
manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: John McGrath,
University of Queensland, Australia
Citation: Holmes E, Tsang TM,
Huang JTJ, Leweke FM, Koethe D, et
al. (2006) Metabolic profiling of CSF:
Evidence that early intervention may
impact on disease progression and
outcome in schizophrenia. PLoS Med
3(8): e327. DOI: 10.1371/journal.
pmed.0030327
Received: January 12, 2006
Accepted: May 26, 2006
Published: August 22, 2006
DOI:
10.1371/journal.pmed.0030327
Copyright:  2006 Holmes et al.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction
in any medium, provided the
original author and source are
credited.
Abbreviations: ASPA,
aspartoacylase; CSF, cerebrospinal
fluid; NAA, N-acetylaspartate; NMR,
nuclear magnetic resonance; OSC,
orthogonal signal correction; PLS-
DA, partial least square discriminant
analysis
* To whom correspondence should
be addressed. E-mail: sb209@cam.ac.
uk
[ These authors contributed equally
to this work.
A B S T R A C T
Background
The identification of schizophrenia biomarkers is a crucial step towards improving current
diagnosis, developing new presymptomatic treatments, identifying high-risk individuals and
disease subgroups, and assessing the efficacy of preventative interventions at a rate that is not
currently possible.
Methods and Findings
1H nuclear magnetic resonance spectroscopy in conjunction with computerized pattern
recognition analysis were employed to investigate metabolic profiles of a total of 152
cerebrospinal fluid (CSF) samples from drug-naı¨ve or minimally treated patients with first-onset
paranoid schizophrenia (referred to as ‘‘schizophrenia’’ in the following text) and healthy
controls. Partial least square discriminant analysis showed a highly significant separation of
patients with first-onset schizophrenia away from healthy controls. Short-term treatment with
antipsychotic medication resulted in a normalization of the disease signature in over half the
patients, well before overt clinical improvement. No normalization was observed in patients in
which treatment had not been initiated at first presentation, providing the first molecular
evidence for the importance of early intervention for psychotic disorders. Furthermore, the
alterations identified in drug-naı¨ve patients could be validated in a test sample set achieving a
sensitivity and specificity of 82% and 85%, respectively.
Conclusions
Our findings suggest brain-specific alterations in glucoregulatory processes in the CSF of
drug-naı¨ve patients with first-onset schizophrenia, implying that these abnormalities are
intrinsic to the disease, rather than a side effect of antipsychotic medication. Short-term
treatment with atypical antipsychotic medication resulted in a normalization of the CSF disease
signature in half the patients well before a clinical improvement would be expected.
Furthermore, our results suggest that the initiation of antipsychotic treatment during a first
psychotic episode may influence treatment response and/or outcome.
The Editors’ Summary of this article follows the references.
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Introduction
The current diagnosis of schizophrenia remains subjective,
not only because of the complex spectrum of symptoms and
their similarities to other mental disorders, but also due to
the lack of empirical disease markers. There is a great clinical
need for diagnostic tests and more effective drugs for the
treatment of severe mental illnesses. An understanding of the
molecular characteristics underlying the disease processes of
schizophrenia is a fundamental prerequisite to the develop-
ment of presymptomatic diagnostics and high-value ther-
apeutics.
Biomarkers derived from global expression proﬁling
techniques performed on readily accessible body ﬂuids, such
as cerebrospinal ﬂuid (CSF), serum, urine, or saliva, can help
identify disease subtypes, aid in predicting and monitoring
treatment response and compliance, and identify novel drug
targets. These biomarkers could also open up the possibility
of developing new early or presymptomatic treatments to
improve outcomes or even prevent pathology. Furthermore,
the validation of biomarkers that can detect early changes
speciﬁcally correlated to reversal or progression of mental
disorders is crucial for intervention. Used as predictors, these
biomarkers could help to identify high-risk individuals and
disease subgroups potentially useful as targets for chemo-
intervention trials, whilst as surrogate endpoints, biomarkers
may be useful for assessing the efﬁcacy and cost effectiveness
of preventative interventions at a speed that is not possible
when the incidence of manifest mental disorder is used as the
endpoint.
1H nuclear magnetic resonance (NMR) spectra of bioﬂuids
and tissues provide a characteristic ‘‘ﬁngerprint’’ for a range
(approximately 20 metabolites can be reliably detected and
quantiﬁed in CSF) of biologically important endogenous
metabolites, such as glucose, lactate and amino acids [1–9].
Quantiﬁable differences in metabolite patterns in bioﬂuids
and tissues can give insight into the underlying molecular
mechanisms of disease and can be characterized using
automated computer programs that present each metabolite
measured in the bioﬂuid spectrum as a coordinate in
multidimensional space. Successful application of this tech-
nology has achieved identiﬁcation of biomarkers for a wide
range of pathologies, including inborn errors of metabolism,
liver and kidney disease, cardiovascular disease, insulin
resistance, and neurodegenerative disorders, amongst others
[3,4,10–13]. Although a wealth of disease studies have been
performed on bioﬂuids such as urine and plasma, relatively
few metabolite proﬁling studies have been performed on CSF
for the purpose of disease diagnosis [14–19]. In this study, we
undertook an extensive metabolic proﬁling analysis of CSF
samples from control individuals and patients with schizo-
phrenia (note that four of the 54 patients investigated had a
diagosis of brief psychotic disorder; i.e., these patients
presented with symptoms of paranoid schizophrenia, but
had not been ill for a minimum of six months at the time of
sample collection, which is required for a DSM IV diagnosis
of schizophenia) using 1H NMR spectroscopy in combination
with computerized pattern recognition analysis. The aim of
this investigation was to identify and characterize a possible
altered biochemical proﬁle of the CSF in patients with
schizophrenia and to determine the metabolic impact of
typical and atypical antipsychotic drugs in drug-treated
patients with schizophrenia.
Methods
Clinical Samples
The Ethical Committee of the Medical Faculty of the
University of Cologne (Cologne, Germany) reviewed and
approved the protocol of this study and the procedures for
sample collection and analysis. All study participants gave
their written informed consent. All clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki. CSF samples were collected from
drug-naı¨ve patients diagnosed with ﬁrst episode paranoid
schizophrenia (hereafter referred to as schizophrenia) or
brief psychotic disorder (n ¼ 4) due to duration of illness
(DSM-IV 295.30 or 298.8; n ¼ 54) and from demographically
matched healthy volunteers (n ¼ 70) (Table 1). Additionally,
samples from patients fulﬁlling DSM-IV criteria of schizo-
Table 1. Demographic Details and CSF and Serum Glucose Levels of Patients
Variable HVs
(n ¼ 70)
PSs,
First Cohort
(n ¼ 37)
PSs,
Second Cohort
(n ¼ 17)
STs
(n ¼ 6)
SATs
(n ¼ 22)
Age (years)a 27.4 6 5.9 28.1 6 9.4 25.0 6 5.6 31.5 6 5.5 29.2 6 10.1
Sexb, male 39 27 12 5 17
Sexb, female 31 10 5 1 5
Glucose (mg/dl), CSF 58.5 6 4.6c 62.3 6 5.5 65.3 6 6.4 65.0 6 5.9 64.9 6 6.4
Glucose (mg/dl), serum 87.2 6 15.0d 93.1 6 14.4 91.5 6 9.9 87.3 6 19.2 103.5 6 24.7
Duration of treatment (days) N/A N/A N/A 9.6 6 8.3 9.2 6 6.2
All data are shown as mean 6 s. d.
aThere is no significant difference in age between the control and disease groups (one-way ANOVA).
bFemale gender is overrepresented in the HV group, but sex appears to have no effect on CSF metabolite profiles (see Figure S1).
cGlucose levels in CSF from HVs were lower than levels in CSF from PSs, STs, and SATs (HVs versus PSs [both cohorts included], p , 0.001; HVs versus SATs, p , 0.001; HVs versus STs, p¼
0.02; one-way ANOVA with Tukey’s test).
dSerum glucose levels are significantly increased only in patients with schizophrenia who were treated with atypical antipsychotics (HV versus SAT, p ¼ 0.05, one-way ANOVA with
Dunnett’s T3 test). There is no significant difference in serum glucose level between other groups.
HV, healthy volunteer; PS, patient with schizophrenia; SAT, patient with schizophrenia who was treated with ‘‘atypical’’ antipsychotic medications; ST, patient with paranoid schizophrenia
who was treated with ‘‘typical’’ antipsychotic medications.
DOI: 10.1371/journal.pmed.0030327.t001
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phrenia (DSM-IV 295.30) undergoing treatment with either
typical (total n¼6: ﬂuphenazine, n¼1; haloperidol, n¼4; and
perazine, n ¼ 1) or atypical (total n ¼ 22: amisulpride, n ¼ 1;
clozapine, n ¼ 1; olanzapine, n ¼ 9; risperidone, n ¼ 8;
quetiapine, n ¼ 2; and ziprasidone n ¼ 1) antipsychotic
medication were also included. Thus, in addition to the
healthy volunteer group, four groups with schizophrenia were
examined in this study: two cohorts of drug-naı¨ve patients
with ﬁrst-onset schizophrenia (n¼37 and n¼17, respectively),
one group of patients with schizophrenia who were treated
with typical antipsychotic medications, and one group of
patients with schizophrenia who were treated with atypical
antipsychotic medications.
Due to an overrepresentation of females in the healthy
volunteer group we examined the effect of gender on the
metabolite proﬁle, but did not ﬁnd a gender-speciﬁc effect
(see Figure S1). We also examined the inﬂuence of recent and
lifetime cannabis use, determined by urine drug screen and
clinical interview, respectively (see Figure S2 and Results).
All samples were collected in a standardized fashion by the
same team of experienced clinicians using a nontraumatic
lumbar puncture procedure. Trained clinical psychiatrists
performed psychiatric assessments. Glucose levels in CSF and
serum from healthy participants and patients with schizo-
phrenia were measured immediately after collection using a
NOVA BioProﬁle analyser (Nova Biomedical, Waltham,
Massachusetts, United States). CSF samples were divided into
aliquots and stored at80 8C. None of the samples underwent
more than two freeze-thaw cycles prior to acquisition of NMR
spectra. All experiments were performed under blind and
randomized conditions. The volume of CSF samples (150 ll)
was made up to a ﬁnal volume of 500 ll by the addition of
D2O in preparation for
1H NMR analysis.
1H NMR Spectroscopy of CSF Samples
Standard one-dimensional 600 MHz 1H NMR spectra were
acquired for all samples using a presaturation pulse sequence
to effect suppression of the water resonance (pulse sequence:
relaxation delay-908-t1-908-tm-908-acquire FID; Bruker Analy-
tische GmbH, Rheinstetten, Germany). In this pulse sequence,
a secondary radio frequency irradiation is applied speciﬁcally
at the water resonance frequency during the relaxation delay
of 2 s and the mixing period (tm¼100 ms), with t1 ﬁxed at 3 ls.
Typically 256 transients were acquired at 25 8C into 32,000
data points, with a spectral width of 6000 Hz and an
acquisition time of 1.36 s per scan. Prior to Fourier
transformation, the FIDs were multiplied by an exponential
weight function corresponding to a line-broadening factor of
0.3 Hz.
Data Reduction and Pattern Recognition Procedure
To efﬁciently evaluate the metabolic variability within and
between bioﬂuids derived from patients and controls, spectra
were digitally analysed using the software program AMIX
(Analysis of MIXtures version 2.5, Bruker Rheinstetten,
Germany) and exported into SIMCA-P (version 10.5, Ume-
trics AB, Umea˚, Sweden), in which a range of multivariate
statistical analyses were conducted. Initially principal com-
ponents analysis was applied to the data in order to discern
the presence of inherent similarities in spectral proﬁles. Only
one spectrum was excluded from the analysis on the basis of
the Hotelling’s t-test, which provides a 95% conﬁdence value
for a model based on the sample composition. Poor water
suppression and high citrate composition were the main
cause of sample exclusion. Where the classiﬁcation of 1H
NMR spectra was inﬂuenced by exogenous contaminants, the
spectral regions containing those signals were removed from
statistical analysis. In order to conﬁrm the biomarkers
differentiating the patients with schizophrenia from matched
controls, partial least square discriminant analysis (PLS-DA)
was employed.
Orthogonal Signal Correction of NMR Data
The orthogonal signal correction (OSC) method removes
variation in the data matrix between samples that is not
correlated with the Y-vector [20]. The resulting dataset was
ﬁltered to allow pattern recognition focused on the variation
correlated to features of interest within the sample popula-
tion, which improves the predictivity and separation power of
pattern recognition methods [4].
Other Statistical Methods
Where appropriate, data were subjected to one-way
ANOVA using the Statistical Package for Social Scientists
(SPSS/PCþ; SPSS, Chicago, Illinois, United States). Where the
F ratio gave p , 0.05, comparisons between individual group
means were made by Tukey’s test for post-hoc comparisons
when the variance was equal between groups. Dunnett’s T3
test was used for post-hoc comparisons if variances are not
equal. Signiﬁcance levels were set at p ¼ 0.05. Experimental
and clinical data were stored in distant research sites, and
correlations and subgroup analyses were performed blind.
Results
Alterations of CSF Metabolic Profiles in First-Onset, Drug-
Naı¨ve, Patients with Schizophrenia
Plots of PLS-DA scores based on 1H NMR spectra of CSF
samples showed a clear differentiation between healthy
volunteers and drug-naı¨ve patients with ﬁrst-onset schizo-
phrenia (Figure 1). The loading coefﬁcients indicated that
glucose, acetate, alanine, and glutamine resonances were
predominantly responsible for the separation between
classes. Results from 1H NMR spectroscopy showed signiﬁ-
cantly elevated glucose concentrations in CSF samples from
drug-naı¨ve patients with ﬁrst-onset schizophrenia, as com-
pared to the demographically matched control group, with a
relative increase in concentration of 6.5% (p ¼ 0.04;
calculated from a distinct resonance signal at 3.68–3.72
ppm). Direct measurements of CSF glucose levels (performed
immediately after sample collection) conﬁrmed a highly
signiﬁcant increase in glucose levels in drug-naı¨ve patients
with schizophrenia in the ﬁrst cohort (6.5% increase, p ¼
0.005; Table 1). Serum glucose levels obtained from the same
patients with schizophrenia and from healthy participants
showed no difference (p ¼ 0.24), suggesting a brain and/or
CSF-speciﬁc elevation in glucose levels. In contrast, acetate
and lactate concentrations were reduced (11.5%, p ¼ 0.006;
and 17.3%, p ¼ 0.05 [t test], respectively) in drug-naı¨ve
patients with schizophrenia from the ﬁrst cohort compared
to matched controls. Spectral changes corresponding to
glutamine and alanine resulted from a pH-dependent change
in the chemical shift of these resonances. CSF samples from
untreated patients with schizophrenia was on average 0.1 pH
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units lower than in the matched control samples (p , 0.05, t
test), which corresponds to a mean chemical shift change of
0.015 ppm for the b-CH2 resonance of glutamine and 0.016
ppm for the alanine CH3 signal.
Effects of Antipsychotic Drug Treatment on CSF Metabolic
Profile in Patients with First-Onset Schizophrenia
Short-term treatment for an average of about nine days
(see Methods and Table 1 for details) with atypical anti-
psychotic medications resulted in a normalization of the CSF
metabolite proﬁle in approximately 50% of patients with
schizophrenia (Figure 2A), whereas treatment with one of the
typical antipsychotic medications did not show such an effect
(Figure 2A). Because the number of patients treated with
typical antipsychotic medications is low (n ¼ 6), however, no
clear conclusions can be drawn from this observation.
Interestingly, we observed that patients who suffered several
psychotic episodes before drug treatment was initiated
(either with typical or atypical antipsychotic medications)
did not show a normalization of their CSF disease proﬁles. Six
out of a total of seven patients with more than one psychotic
episode before drug treatment cluster closely with the drug-
naı¨ve schizophrenia group and, indeed, none of them cluster
with the healthy control group (Figure 2B). Moreover, all
patients with schizophrenia who exhibited a normalization of
the CSF metabolite proﬁle (either with typical or atypical
antipsychotic medications) had been commenced on medi-
cation during their ﬁrst psychotic presentation. In statistical
terms (recognizing that the numbers are small), our study
suggests that if treatment is initiated during a ﬁrst episode,
some of the patients (58% in this study) may recover normal
CSF metabolite proﬁles, whereas if medication is given after a
second psychotic episode, normalization may not occur or
may be more rare (none of the seven patients showed
normalization). Note that experimental and clinical data were
stored in distant research sites; all experiments and sub-
sequent data analyses were performed blind to avoid
experimental bias.
Due to the prevalent cannabis use amongst patients with
schizophrenia and the known effect of cannabis on glucor-
egulation, we examined the inﬂuence of this potential
confounding factor in the disease and control groups. None
of the control patients had tested positive on urine drug
screen and no change in CSF metabolites was observed
between healthy volunteers who reported moderate (20–50
times per lifetime) or low/no (,5 times per lifetime) cannabis
Figure 1. Metabonomic Analysis of CSF Samples from Drug-Naı¨ve Patients with Schizophrenia
(A) Partial 1H NMR spectrum of a CSF sample from a representative drug-naı¨ve patient with first-onset schizophrenia (red) and a matched control (black)
illustrate a characteristic pH-dependent shift in the b-CH2 and c-CH2 resonances of glutamine. The prominent signals at ;3.7 and 1.2 ppm correspond
to ethanol, a contaminant from skin disinfection prior to lumbar puncture. These signals were removed from statistical analysis.
(B) PLS-DA scores plot showing a differentiation of drug-naı¨ve patients with schizophrenia from demographically matched controls as determined by
the 1H NMR CSF spectra.
(C) PLS-DA loadings plot showing major contributing variables towards the separation in the PLS-DA scores plots.
DOI: 10.1371/journal.pmed.0030327.g001
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use (unpublished data). In the drug naı¨ve group with
schizophrenia, seven patients (out of a total of 37 in the ﬁrst
cohort) tested positive for cannabis on urine drug screen.
Cannabis-positive patients had signiﬁcantly lower serum
glucose levels (9% decrease; p ¼ 0.05, t test), but no effect
on CSF glucose levels was observed (p¼ 0.20, t test; see Table
S1). Three patients who tested positive for cannabis were
found to have highly altered CSF metabolite proﬁles and
formed a separate cluster in the PLS-DA plot (away from both
healthy controls and patients with schizophrenia) whilst the
remaining four cannabis-positive patients clustered with the
drug-naı¨ve schizophrenia group (Figure S2).
Validation of Key Metabolic Alterations in an Independent
Test Sample Set
To validate our ﬁndings, we reanalyzed samples from the
ﬁrst cohort (70 controls and 37 drug-naı¨ve patients with ﬁrst-
onset schizophrenia CSF samples), alongside a second cohort
of 17 additional drug-naı¨ve patients with ﬁrst-onset schizo-
phrenia. A model was built based on a training set of 50
randomly selected control samples and the 37 samples from
drug-naı¨ve patients with ﬁrst-onset schizophrenia from the
ﬁrst cohort. Both principal components analysis and PLS-DA
showed results similar to those in Figure 1 (see also Figure S3).
This model was then used to predict class membership in a
test set comprising 20 control CSF samples (from the ﬁrst
cohort) and 17 drug-naı¨ve patients with ﬁrst-onset schizo-
phrenia (from the second cohort, Table 1). OSC was applied
to enhance the metabolic differentiation between classes
within the model [4]. After OSC, separation of control and
drug-naı¨ve with ﬁrst-onset schizophrenia groups in the PLS
scores plots (Figure 3A) was characterized by similar spectral
regions as previously identiﬁed to contribute to the separa-
tion of the classes—i.e., glucose, lactate, shifts in glutamine
resonances, and citrate (Figure 3B). The PLS model calculated
Figure 2. Effects of ‘‘Typical’’ and ‘‘Atypical’’ Medication on CSF
Metabolic Profiles in Patients with First-Onset Schizophrenia
(A) Spectra from 28 CSF samples from patients with first-onset
schizophrenia minimally treated (,9 d, see text for details) with either
typical (n ¼ 6, blue diamonds) or atypical (n ¼ 22, green circles)
antipsychotic medications were compared to first onset, drug naı¨ve
patients (red triangles) and healthy volunteers (black squares) using PLS-
DA. The PLS-DA scores plots show that atypical antipsychotic drug
treatment resulted in a shift of approximately 50% of patients with
schizophrenia towards the cluster of healthy controls.
(B) The same PLS-DA scores plot as (A) except that only minimally treated
patients (from both drug groups) with more than one psychotic episode
prior to antipsychotic treatment are shown. Note that none of these
patients shifted towards the healthy control cluster.
DOI: 10.1371/journal.pmed.0030327.g002
Figure 3. Validation and Prediction of Schizophrenia Group Membership
Using a PLS Model
A PLS model was constructed using the OSC-filtered data from 37 drug-
naı¨ve patients with first-onset schizophrenia from the first cohort (red
points) and 50 randomly selected healthy volunteers (blue points) (the
‘‘training set’’). The scores plot (A) and the loadings plot (B) indicate the
key resonances contributing to the separation: lactate, glucose,
glutamine, and citrate. This model was then used to predict ‘‘group
membership’’ (i.e., schizophrenia or control) in a test set of 17 drug-naı¨ve
patients (second cohort) with first-onset schizophrenia and the remain-
ing 20 healthy volunteers which had not been used in the construction
of the model. Predictions are made using a Y-predicted scatter plot with
an a priori cut-off of 0.5 for class membership (C).
DOI: 10.1371/journal.pmed.0030327.g003
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from OSC-ﬁltered NMR data was then used to predict class
membership in the test sample set. The Y-predicted scatter
plot assigned samples to either the control or the schizo-
phrenia group using an a priori cut-off of 0.5, and showed the
ability of 1H-NMR metabonomics analysis to predict class
membership of unknown samples with a sensitivity of 82%
and a speciﬁcity of 85% (Figure 3C).
Discussion
Analysis of the 1H NMR spectra of CSF samples showed a
differential distribution of metabolites in samples from
healthy volunteers away from drug-naı¨ve patients with ﬁrst-
onset schizophrenia (Figure 1B and 1C). The metabolic
proﬁle of CSF was characteristically altered in patients with
schizophrenia, and the majority of key metabolites contribu-
ting to the separation were replicated in an independent test
set (Figure 3). There was some overlap between the ﬁrst
cohort of drug-naı¨ve patients with ﬁrst-onset schizophrenia
and controls in the PLS-DA scores plot derived from the
NMR spectra (Figure 1B and 1C). Whilst the drug-naı¨ve
patients with ﬁrst-onset schizophrenia clustered very tightly
together, a small number of samples did not show a clear
separation in the PLS-DA analysis. This may indicate the
existence of schizophrenia subgroups, and it will be of
interest to explore whether clinical parameters, such as
disease progression, severity, and/or drug response relate to
distinct metabolic signatures. Although the sample size of this
study is too small to make assumptions about patient
subgroups, we note that the four patients who clustered with
the control group (Figure 1B) had an exceptionally good
outcome or recovered fully from a ﬁrst episode of psychosis.
Abnormal glucose levels in serum have been linked to
antipsychotic drug treatment [21,22], yet our observation of
an elevation of CSF glucose concentrations in patients with
schizophrenia implies that glucoregulatory alterations may be
intrinsic to the schizophrenia syndrome as well as brain-
speciﬁc, since (1) CSF samples collected from drug-naı¨ve,
ﬁrst-onset patients showed signiﬁcantly increased glucose,
and (2) sera from the same patients showed no such glucose
elevation. Elevated CSF glucose has not previously been
reported for schizophrenia; however, abnormally high fasting
glucose tolerance has been observed in serum from ﬁrst-onset
patients [23]. It is of interest that the prevalence of diabetes
type II is substantially increased in patients with schizophre-
nia (15.8%, compared to 2%–3% in the general population)
[24]. Studies also found increased plasma levels of glucose and
norepinephrine in patients with schizophrenia [25–27],
although increased serum glucose and the high prevalence
of type II diabetes in these patients have mainly been
attributed to antipsychotic drug treatment [21,27]. Indeed,
we found serum glucose levels increased in patients treated
with atypical antipsychotic medication (Table 1). It is possible
that drug treatment precipitates the onset of diabetes in
patients with schizophrenia in the context of a co-predis-
position, and that both schizophrenia and diabetes type II
share common disease mechanisms. Our recent study inves-
tigating global gene, protein, and metabolite alterations in
schizophrenia postmortem brain tissue demonstrated signiﬁ-
cant alterations of pathways relating to glucoregulation and
mitochondrial function [37], further supporting the notion of
disturbed glucose metabolism in the brains of patients with
schizophrenia.
Additionally, a signiﬁcantly lowered CSF pH aligns very
well with our observations in postmortem brain and with
alterations observed in energy metabolism at large [37].
Several other studies on postmortem brain also found
mitochondrial changes in schizophrenia (e.g., [28,29]). The
lowered pH observed in CSF in this study may thus be due to
alterations in cellular respiration. Surprisingly, however,
although we identiﬁed an increase in lactate in postmortem
brain tissue, we observed a signiﬁcant decrease in CSF lactate
levels in patients with ﬁrst-onset schizophrenia. At this stage
we are unable to pinpoint which metabolite alterations are
contributing to the lowered pH in CSF. A possible explan-
ation could be that the ‘‘schizophrenia brain’’ preferentially
utilizes lactate over glucose as an energy substrate. Brain
lactate is believed to be predominantly produced by
astrocytes [30] and is used as energy substrate in brain,
especially by neurons under certain physiological conditions
[30]. In fact, signiﬁcant monocarboxylate utilization by the
brain was also reported in different pathological states such
as diabetes and prolong starvation [31,32].
Acetate was also signiﬁcantly reduced in the CSF of drug-
naı¨ve patients with ﬁrst-onset schizophrenia. Since a major
portion of acetate in the brain is utilised in fatty acid and
lipid synthesis [33], the decreased acetate concentration may
suggest a compromised synthesis of myelin-related fatty acids
and lipids in the schizophrenia brain. Acetate in the brain is
primarily derived from N-acetylaspartate (NAA), which is
hydrolyzed into L-aspartate and acetate by the enzyme
aspartoacylase (ASPA) [34]. NAA is synthesized in neuronal
mitochondria and transferred to oligodendrocytes, where
ASPA liberates the acetate moiety to be used for myelin lipid
synthesis [35]. An in vivo reduction in NAA levels in
schizophrenia is a well-established observation [36]. Further-
more, we found ASPA transcripts down-regulated in post-
mortem brain by microarray and quantitative PCR analysis in
schizophrenia postmortem brain (1.78, p ¼ 0.09 by micro-
array; 1.61, p ¼ 0.04 by quantitative PCR; n ¼ 15
schizophrenia prefrontal cortex and matched controls [un-
published data]). Together with our ﬁndings of a signiﬁcant
decrease of acetate in CSF, this lends further support not
only for altered NAA metabolism, but also for oligodendro-
cyte dysfunction, which we and others previously reported
[37,38]. Perturbations in CSF acetate concentrations have
also been observed in patients with Creutzfeldt-Jakob disease,
although in contrast to the current study, Creutzfeldt-Jakob
disease was associated with an increase in acetate concen-
trations [39].
The speciﬁcity of the metabolic signature for schizophrenia
found in this study remains to be veriﬁed. Disturbed glucose
metabolism has also been associated with mood and psychotic
disorders [40], although to our knowledge none of these
studies measured CSF glucose levels. However, the increased
concentrations of glucose together with other metabolic
perturbations, such as lower levels of acetate and lactate, and
a pH-dependent shift in glutamine resonances, may represent
a more speciﬁc disease diagnostic for schizophrenia.
The effects of two drug treatment regimens—the use of
typical and atypical antipsychotic medication—were eval-
uated using the same analytical methods. Normalization of
the metabolite proﬁles was observed in patients (n¼ 28) who
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had been treated with atypical antipsychotic medication for
an average of about nine days. Figure 2 illustrates a shift of
approximately 50% (11 of 22) of patients on atypical
antipsychotic medications towards the cluster of healthy
controls within the PLS-DA plot. Although certainly pre-
liminary, these results suggest that atypical medication
results in a normalization of the metabonomic disease
signature. Only between 40% and 70% (according to
different sources) of patients with schizophrenia respond
to antipsychotic intervention. Clinical response is generally
observed only after weeks or months of treatment. Thus it
will be of great interest to examine whether normalization of
the metabonomic signature is predictive of clinical drug
response. If the normalizing response, which occurs after
only a few days of treatment, is conﬁrmed in larger future
studies, this could revolutionise schizophrenia treatment and
drug discovery approaches. As the sample size of individual
antipsychotic drugs in this study was too small to evaluate
metabolic effects of each drug, further studies are also
required to evaluate their speciﬁc effects of individual
medications.
A striking ﬁnding of this study is the effect of number of
psychotic episodes prior to commencing antipsychotic treat-
ment on the CSF metabolite proﬁle in patients with
schizophrenia. Again, the numbers were relatively small, but
of 21 patients who were commenced on antipsychotic
medication during their ﬁrst psychotic episode, 57% clus-
tered with healthy controls, whereas six out of the seven
patients who had several psychotic episodes prior to treat-
ment clustered with the group of drug-naı¨ve patients with
ﬁrst-onset schizophrenia (Figure 2B). These results suggest
that the initiation of antipsychotic treatment during a ﬁrst
psychotic episode may inﬂuence treatment response and/or
indeed outcome. This view is in agreement with the Personal
Assessment and Crisis Evaluation (PACE) clinic study [41], the
Prevention through Risk Identiﬁcation, Management and
Education (PRIME) study [42] and other ongoing studies that
support the notion that early identiﬁcation and treatment of
patients at risk of developing schizophrenia may reduce
morbidity and adverse outcomes. Metabonomic approaches
of proﬁling CSF may provide a novel avenue of achieving
both early diagnosis and aid in monitoring therapeutic
intervention for schizophrenia.
Many patients with schizophrenia are recreational canna-
bis users, and cannabis has a known effect on glucoregulation;
thus we examined this potential confounding factor very
closely. We found that recent cannabis use was associated
with a signiﬁcant reduction in serum glucose, but observed
no inﬂuence on the CSF metabolite proﬁle (Figure S2 and
Table S1).
In summary, we suggest that the application of metabolite
proﬁling tools can provide an efﬁcient means for early
diagnosis of schizophrenia and provide a practical method
for monitoring therapeutic intervention by providing metrics
for the normalization of bioﬂuid spectra by multivariate
comparison with the relevant control proﬁles.
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Editors’ Summary
Background Biological markers, or ‘‘biomarkers,’’ are combinations of
molecules that are present in certain diseases. Scientists are interested in
discovering new biomarkers because they could be useful for diagnosis
of those diseases. The presence of such biomarkers might in some cases
even precede the development of disease symptoms, which could help
in early diagnosis, treatment, and maybe even prevention. Schizophrenia
is a disease for which no ‘‘objective’’ biological test exists, and scientists
are trying to find biomarkers that would help with diagnosis. The current
diagnosis of schizophrenia is based on the symptoms experienced and
reported by the patient, in combination with signs observed by a
psychiatrist, clinical psychologist, or other clinician.
Why Was This Study Done? This study was done to search for
biomarkers for schizophrenia. The researchers studied the metabolic
state of patients and healthy volunteers (controls). In other words, they
focused on the small molecules present in cells, tissues, or body fluids.
The metabolic state reflects what has been encoded by a person’s genes
and modified by environmental factors. Focusing on the metabolic state
makes sense for a disease like schizophrenia, since many different
genetic and environmental factors are thought to be responsible for
causing it.
What Did the Researchers Do and Find? The researchers studied the
metabolic state of 82 patients with schizophrenia and 70 healthy
controls by studying the levels of different molecules present in their
cerebrospinal fluid (the clear body fluid that surrounds the brain and the
spinal cord). Of the patients, 54 had just been diagnosed with
schizophrenia (or a similar illness called brief psychotic disorder) and
had not yet taken any medications to treat schizophrenia (so-called
antipsychotic medication). The remaining patients were undergoing
treatment with a range of antipsychotic drugs. The researchers found
different levels of certain molecules in the spinal fluid of newly
diagnosed patients who had never taken schizophrenia drugs compared
with healthy individuals of the same ages. These molecules might
therefore turn out to be useful biomarkers for schizophrenia. The
differences between patients and controls suggested that the metab-
olism of several substances—including glucose and acetate—might be
altered in the brains of patients with schizophrenia or brief psychotic
disorder. The researchers also found that the levels of these molecules in
some of the patients with newly diagnosed schizophrenia who were
given medication became similar to the levels in the control individuals.
What Do These Findings Mean? These results are encouraging because
they suggest that studying ‘‘metabolic profiles’’ might lead to finding a
set of biomarkers that could reliably help in early diagnosis of
schizophrenia. Such biomarkers might possibly also help in monitoring
patients’ responses to drug treatment. However, as acknowledged by
the study’s authors and emphasized by Rima Kaddhurah Daouk in an
accompanying Perspective, these early results need to be tested in larger
studies and confirmed before their clinical relevance will be known. It will
be important for such follow-up studies to involve patients with other
psychiatric diseases (not just schizophrenia), to see whether the
biomarkers are specific to schizophrenia or whether they indicate a
broader range of psychiatric diseases.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030327.
 National Institutes of Mental Health pages on schizophrenia
 The National Alliance for Research on Schizophrenia and Depression
 The National Alliance for the Mentally Ill
 The Schizophrenia Society of Canada
 Wikipedia page on schizophrenia (note: Wikipedia is an online
encyclopedia that anyone can edit)
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